Comparison of safety and immunogenicity between high-dose and low-dose quadrivalent influenza vaccines in children aged 6–35 months in China: A randomized, double-blind clinical study Authors: Xue Guo, Jingyu Li, Xufeng Dong, Kunpeng Xing, Xiaoteng Xu, Wen Xu, Cangning Wang, Kexin Li, Xuefen Gao, Ye Qiu, Zhanlong Guo, Weijiao Xu, Chenyan Zhao, Yuanjia Ma, Yehong Wu, Xiaoqiang Liu, Guohua Li Published: 2026 ABSTRACT ABSTRACTInfluenza vaccines for children aged 6–35 months are typically low-dose (0.25 mL, 7.5 μg hemagglutinin per strain). However, studies have shown that high-dose influenza vaccines (0.5 mL, 15 μg hemagglutinin per strain) can enhance protective efficacy without increasing the risk of adverse reactions. We conducted a randomized, double-blind clinical study in children aged 6–35 months in China. A total of 3,000 participants were randomized (1:1:1) to receive two doses of either an investigational high-dose quadrivalent influenza vaccine (H-QIV), an investigational low-dose quadrivalent influenza vaccine (LQIV-01) or a commercially available low-dose quadrivalent influenza vaccine (LQIV-02). Hemagglutination inhibition (HI) antibody titers 30 d post-vaccination were measured and vaccine safety and tolerability within 6 months post-vaccination were evaluated in these participants. The primary objectives were to demonstrate the non-inferiority of investigational vaccines to the commercially available vaccine in immunogenicity and to compare the H-QIV to L-QIVs. Both investigational vaccines demonstrated non-inferiority, with their seroprotection rates (SPRs), seroconversion rates (SCRs) and geometric mean titers (GMTs) meeting immunogenicity criteria. The H-QIV exhibited >11-fold increases in GMTs against H1N1, H3N2, B/Yamagata and B/Victoria strains compared to pre-vaccination levels, with SPRs exceeding 95% and SCRs exceeding 89%. The H-QIV was superior to both L-QIVs as it induced a stronger immune response to influenza viruses. All vaccines showed comparable safety profiles. The H-QIV can provide greater protection and benefits to this high-risk population.KEYWORDS: Quadrivalent influenza vaccine, aged 6–35 months, immunogenicity, safety, clinical trials Introduction Influenza is a highly contagious respiratory disease.1 The World Health Organization (WHO) estimates that seasonal influenza epidemics cause 3 to 5 million severe cases and 290,000 to 650,000 respiratory deaths annually worldwide.2,3 The general population is susceptible to influenza viruses, with children having a higher incidence than adults.4 Due to their immature immune systems and dense behavioral patterns, children are at a higher risk of influenza, potentially leading to hospitalization and death, especially in those aged <5 y,5 imposing considerable socioeconomic and clinical burdens.6 Currently, influenza vaccines have not been included in the National Immunization Program (NIP) in China. According to the recommendations of the Chinese Center for Disease Control and Prevention, priority groups for influenza vaccination include children aged 6–59 months, the elderly, patients with chronic diseases, healthcare providers, pregnant women, and caregivers of infants aged <6 months.7 In China, approved influenza vaccines include trivalent inactivated influenza vaccine (TIV), live attenuated trivalent influenza vaccine (LTIV) and quadrivalent inactivated influenza vaccine (QIV). Prior to this study, QIVs approved in China were limited to a 0.5 mL dose for individuals aged >3 y; only one manufacturer’s split-virion QIV (IIV4) offered a 0.25 mL dose for individuals aged 6–35 months. Clinical studies have shown that high-dose influenza vaccines (0.5 mL) exhibit superior immunogenicity to low-dose vaccines in children aged 6–35 months.8,9 Given that young children are at a high risk of influenza, there is an urgent need for influenza vaccines indicated for children aged <3 y. This study aimed to evaluate the immunogenicity and safety of QIVs manufactured by Changchun Institute of Biological Products Co., Ltd. (CCIBP) in children aged 6–35 months in China, including a comparison between high-dose and low-dose vaccines. Methods Study design This was a multicenter, randomized, double-blind, controlled Phase II clinical study (ChiCTR2200064959) conducted from October 2022 to September 2023 involving 3,000 healthy participants aged 6–35 months. These participants were randomized (1:1:1) to receive 2 doses of either H-QIV (high-dose quadrivalent influenza vaccine), LQIV-01 (low-dose quadrivalent influenza vaccine, group 01)or LQIV-02 (low-dose quadrivalent influenza vaccine, group 02). CCIBP sponsored and supervised the clinical study. Yunnan and Shanxi Centers for Disease Control and Prevention were responsible for vaccine management and safety and immunogenicity data collection. Suzhou Panacro Pharmaceutical Technology Co., Ltd. was responsible for statistical analysis of study data. The National Institutes for Food and Drug Control (NIFDC) was responsible for vaccine and serum antibody evaluation. The entire study was approved by the Ethics Committee in accordance with the Declaration of Helsinki and the Good Clinical Practice issued by the National Medical Products Administration (NMPA) of China. Parents or guardians of participants were fully informed and signed Informed Consent Forms before clinical enrollment. Study participants Eligible participants were healthy children aged 6–35 months, born full-term with a birth weight of ≥2,500 g. Exclusion criteria: (1) Axillary temperature >37°C; (2) History of influenza within the past year; (3) History of influenza vaccination before the season; (4) History of severe allergy to any vaccine or drug; (5) History of dystocia, rescue for asphyxia or neurological impairment; (6) Congenital malformations or developmental disorders affecting organ function, genetic defects or severe malnutrition; (7) Acute diseases, severe chronic diseases or acute exacerbation of chronic diseases on the day of vaccination; (8) Receipt of a live attenuated vaccine within 14 d or any other vaccine within 7 d pre-vaccination; (9) Receipt of blood products or blood-related products, immunostimulant or immunosuppressants within 3 months pre-vaccination; (10) Progressive neurological diseases, history of convulsion, epilepsy, encephalopathy or Guillain-Barré syndrome, or personal or family history of psychosis; (11) Any factors deemed to make the participant unsuitable for the clinical study. Vaccines Since the study was conducted between 2022 and 2023, the QIVs used in this study complied with WHO’s recommendations for influenza vaccine composition for the 2022–2023 northern hemisphere influenza season. All contained the following four virus strains: A/Victoria/2570/2019(H1N1)pdm09-like virus, A/Darwin/9/2021(H3N2)-like virus, B/Austria/1359417/2021(B/Victoria lineage)-like virus and B/Phuket/3073/2013(B/Yamagata lineage)-like virus. Both L-QIVs were 0.25 mL/dose, containing 7.5 μg hemagglutinin per influenza virus strain. Specifically, the investigational vaccine LQIV-01 (batch No.: SQ20220402) was manufactured by CCIBP, while the control vaccine LQIV-02 (batch No.: 202204C034) was manufactured by Hualan Biological Vaccine Inc., Ltd. and approved in China. The H-QIV (Batch No.: Q20220513) was 0.5 mL/dose, containing 15 μg hemagglutinin per strain, and was also manufactured by CCIBP. Participants received one of the vaccines intramuscularly in two doses, 28 d apart. Randomization and Double-Blind The design for randomization and blinding was entrusted to an independent third party. All vaccines were randomly assigned and participants were enrolled sequentially. First, three sets of identical randomization numbers were generated using SAS software. Then, all vaccines were re-labeled with randomization numbers, ensuring the vaccine number was consistent with the participant’s randomization number. Finally, each participant was assigned a randomization number in the order of their enrollment and given the corresponding vaccine. The investigational and control vaccines were identical in appearance and packaging, differing only in dosage. This study adopted a double-blind design. An unblinded team was set up to handle vaccination procedures. Participants and all study staff (except for the unblinded team) remained blinded. The personnel responsible for blinding were only involved in blinding tasks and strictly prohibited from participating in any other part of the study. Safety endpoints All participants underwent a 30-minute medical observation after each dose. A diary card was used to record the occurrence and severity of any adverse events (AEs) within 7 d after each dose. A contact card was used to record any AEs and concomitant medications from Day 8 to Day 28 after the first dose and from Day 8 to Day 30 after the second dose. Additionally, any serious adverse events (SAEs) from 30 d to 6 months after full-course vaccination were recorded via telephone. The grading criteria for adverse reactions and the list of solicited AEs were developed in accordance with the Guidelines for Adverse Event Classification Standards for Clinical Trials of Preventive Vaccines issued by NMPA. Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe, Grade 4 was life-threatening and Grade 5 was fatal. Solicited AEs, pre-defined in the study protocol, included vaccination site AEs (pain, erythema, swelling, induration, pruritus) and systemic AEs (pyrexia, nausea, vomiting, diarrhea, decreased appetite, irritability or listlessness, and hypersensitivity). Immunogenicity endpoints The primary objective was to demonstrate the non-inferiority of H-QIV and LQIV-01 to LQIV-02 in immunogenicity 30 d after full-course vaccination. Primary endpoints: The lower limit of the two-sided 95% confidence interval (CI) for the GMT ratio (GMTLQIV-01/LQIV-02; GMTH-QIV/LQIV-02) ≥0.67; the lower limit of the two-sided 95% CI for the SCR difference (SCRLQIV-01/LQIV-02; SCRH-QIV/LQIV-02) ≥−10%.10 The second objective was to demonstrate the superiority of H-QIV to both L-QIVs in immunogenicity. Secondary endpoints: The lower limit of the two-sided 95% CI for the GMT ratio (GMTH-QIV/LQIV-01; GMTH-QIV/LQIV-02) ≥1; the lower limit of the two-sided 95% CI for the SCR difference (SCRH-QIV/LQIV-01; SCRH-QIV/LQIV-02) ≥0; SCR, defined as the proportion of participants with either a pre-vaccination HI titer <1:10 and a post-vaccination HI titer ≥1:40, or a pre-vaccination HI titer ≥1:10 and a ≥ 4-fold increase in post-vaccination HI antibody titer; SPR, defined as the proportion of participants with a post-vaccination serum HI antibody titer ≥1:40. Serological methods Blood samples were collected pre-vaccination (day 0) and 30 d post-second dose. HI antibody titers were determined by micro-hemagglutination inhibition test at NIFDC. Serial twofold dilutions of serum (starting at 1:10) were incubated with strain-specific hemagglutinin antigens and 1% chicken erythrocytes. The HI titer was defined as the highest dilution completely inhibiting hemagglutination. HI Titers <1:10 were recorded as 5. Statistical analysis In this study, the sample size was calculated using PASS 2021, based on the GMT (assuming one-sided significance level α = 0.025, coefficient of variation = 2, total power = 90% and non-inferiority margin = 0.67) and SCR (assuming total power = 90%, one-sided significance level α = 0.025 and non-inferiority margin = −10%) of the approved LQIV-02. Subsequently, the maximum sample size of 701 per group derived from the two calculations was selected as the baseline. Considering that immunogenicity test values of influenza vaccines are susceptible to environmental variations, the planned enrollment was increased to 1,000 participants per group (3,000 in total) to ensure adequate power for the non-inferiority assessment.If the primary objective was met, a superiority evaluation was conducted. All statistical analyses were performed using SAS (v9.4). Baseline demographic characteristics (age, gender, height and weight) were summarized for all participants. For immunogenicity analysis, the two-sided 95% CIs for SCRs were calculated using the Clopper-Pearson method, and intergroup differences in SCRs were tested using the Chi-square test/Fisher’s exact test; the GMTs and geometric mean increases (GMIs) along with their 95% CIs were calculated for each group, and intergroup differences in GMTs and GMIs were tested using analysis of variance (ANOVA) with log-transformed data. For safety analysis, intergroup differences in the incidences of the above AEs were tested using Fisher’s exact test/Chi-square test. Results Participant disposition A total of 3,389 individuals were recruited in Yunnan Province and Shanxi Province, China. Of these, totally 3,000 participants were enrolled and randomized into LQIV-01, H-QIV and LQIV-02 groups. All participants who received at least 1 dose were included in the Safety Set (SS, N = 2995). Due to the impact of the COVID-19 pandemic, many participants missed the scheduled vaccinations and blood collection windows and were not expected to comply with the protocol-defined procedures. Consequently, 2,598 participants were included in the Per-Protocol Set (PPS), accounting for 86.6% of the total number of participants (Figure 1). LQIV-01, H-QIV and LQIV-02 groups were similar in the proportion of participants, age, gender, height and weight (Table 1). Enrollment and follow-up of the clinical study. Table 1.Demographic characteristics of study participants.Characteristic (SS) LQIV-01H-QIVLQIV-02Participant, No. 999999997Age (months, mean ± SD) 21.9 ± 8.5821.9 ± 8.4322.1 ± 8.45Gender, No. (%)Male521 (52.2%)525 (52.6%)481 (48.2%) Female478 (47.8%)474 (47.4%)516 (51.8%)Height (cm, mean ± SD) 83.54 ± 8.16683.58 ± 8.13683.68 ± 8.304Weight (kg, mean ± SD) 11.66 ± 2.23411.67 ± 2.22011.69 ± 2.291 Demographic characteristics of study participants. Safety The incidences of AEs are shown in Table 2. The incidences of AEs within 30 minutes, 7 d and 30 d after full-course vaccination were 3.5%, 3.5% and 3.0%, 36.8%, 37.1% and 39.8%, and 66.7%, 65.8% and 68.4% in LQIV-01, H-QIV and LQIV-02 groups respectively, with no statistically significant intergroup difference. Within 30 d post-vaccination, the AEs were predominantly Grade 1/2 and the incidences of Grade ≥3 AEs were 12.4%, 11.6% and 12.1% in LQIV-01, H-QIV and LQIV-02 groups respectively, with no statistically significant intergroup difference. Within 30 d post-vaccination, the incidences of solicited AEs were 29.0%, 26.3% and 29.3% and the incidences of unsolicited AEs were 57.4%, 54.7% and 57.5% in LQIV-01, H-QIV and LQIV-02 groups respectively.A total of 301 SAEs were reported. The incidences of SAEs were 9.9%, 9.6% and 10.6% in LQIV-01, H-QIV and LQIV-02 groups respectively, with no statistically significant intergroup difference. Only 3 SAEs were vaccination-related,all requiring hospitalization and subsequently resolving with discharge:1 in the H-QIV group (diarrhea) and 2 in the LQIV-02 group (Henoch-Schonlein purpura and pyrexia). Vaccination-related local and systemic ADRs are detailed in Table 3; the most common systemic ADR was pyrexia and the most common local ADR was injection-site erythema, with no significant intergroup differences. Table 2.Analysis of AEs post-vaccination by group. LQIV-01N = 999H-QIVN = 999LQIV-02N = 997PClassificationn(%)n(%)n(%)AEs within 30 min post-vaccination35 (3.5%)35 (3.5%)30 (3.0%).7773AEs within 7 d post-vaccination368 (36.8%)371 (37.1%)397 (39.8%).3189AEs within 30 d post-vaccination666 (66.7%)657 (65.8%)682 (68.4%).4441Grade ≥ 3 AEs124 (12.4%)116 (11.6%)121 (12.1%).6939Solicited AEs within 30 d post-vaccination290 (29.0%)263 (26.3%)292 (29.3%).2654Solicited local AEs within 30 d post-vaccination45 (4.5%)43 (4.3%)44 (4.4%).9765Solicited systemic AEs within 30 d post-vaccination264 (26.4%)234 (23.4%)268 (26.9%).1570Unsolicited AEs within 30 d post-vaccination573 (57.4%)546 (54.7%)573 (57.5%).3559SAEs within 6 months post-vaccination99 (9.9%)96 (9.6%)106 (10.6%).7373SAR01 (0.1%)2 (0.2%).3327AE: adverse event; SAE: serious adverse event; SAR: serious adverse reaction. Analysis of AEs post-vaccination by group. AE: adverse event; SAE: serious adverse event; SAR: serious adverse reaction. Table 3.Analysis of local and systemic ADRs post-vaccination by group.ClassificationLQIV-01N = 999n(%)H-QIVN = 999n(%)LQIV-02N = 997n(%)PLocal ADRs45 (4.5%)43 (4.3%)44 (4.4%).9807Erythema29 (2.9%)26 (2.6%)21 (2.1%).5318Pain9 (0.9%)7 (0.7%)8 (0.8%).9061Swelling8 (0.8%)13 (1.3%)12 (1.2%).5115Pruritus5 (0.5%)3 (0.3%)6 (0.6%).5676Induration4 (0.4%)4 (0.4%)8 (0.8%).3634Systematic ADRs183 (18.3%)171 (17.1%)202 (20.3%).1926Pyrexia182 (18.2%)171 (17.1%)202 (20.3%).1877Peripheral swelling1 (0.1%)001.0000Diarrhea49 (4.9%)37 (3.7%)38 (3.8%).3344Vomiting30 (3.0%)40 (4.0%)46 (4.6%).1611Nausea7 (0.7%)7 (0.7%)7 (0.7%)1.0000Oral mucosal blistering1 (0.1%)001.0000Abdominal distension01 (0.1%)3 (0.3%).1352Abdominal pain01 (0.1%)1 (0.1%).7774Enteritis01 (0.1%)01.0000Dyspepsia01 (0.1%)01.0000Mouth ulceration001 (0.1%).3329Cough46 (4.6%)35 (3.5%)37 (3.7%).4030Rhinorrhoea35 (3.5%)36 (3.6%)40 (4.0%).8255Nasal obstruction2 (0.2%)1 (0.1%)1 (0.1%)1.0000Sneezing2 (0.2%)01 (0.1%).5549Oropharyngeal pain2 (0.2%)00.3331Dyspnoea1 (0.1%)01 (0.1%).7774Tachypnoea1 (0.1%)001.0000Productive cough01 (0.1%)1 (0.1%).7774Decreased appetite27 (2.7%)22 (2.2%)40 (4.0%).0534Irritability14 (1.4%)11 (1.1%)17 (1.7%).4998Emotional poverty1 (0.1%)2 (0.2%)2 (0.2%).8762Hypersensitivity9 (0.9%)3 (0.3%)10 (1.0%).1250Rash erythematous2 (0.2%)1 (0.1%)0.7776Rash1 (0.1%)3 (0.3%)0.3329Blister1 (0.1%)001.0000Eczema infantile1 (0.1%)001.0000Rash vesicular01 (0.1%)1 (0.1%).7774Dermatitis herpetiformis01 (0.1%)1 (0.1%).7774Hyperhidrosis01 (0.1%)01.0000Papule01 (0.1%)01.0000Night sweats001 (0.1%).3329Henoch-Schonlein purpura001 (0.1%).3329Gastroenteritis1 (0.1%)001.0000Pharyngitis01 (0.1%)1 (0.1%).7774Upper respiratory tract infection001 (0.1%).3329Eye discharge01(0.1%)01.0000ADR: adverse drug reaction. Analysis of local and systemic ADRs post-vaccination by group. ADR: adverse drug reaction. Immunogenicity At baseline, the proportions of participants with pre-vaccination HI antibody titers <1:10 and <1:40 were comparable across the three groups (Table 4), and the pre-vaccination GMTs for each strain were similar among groups (Table 5), indicating balanced immunological backgrounds prior to vaccination.The influenza vaccines induced specific HI antibody responses against all vaccine strains after vaccination (Table 5). The lowest lower limit of the two-sided 95% CI for SCR was 71.45% across groups and strains. The SPRs (proportion of participants with a post-vaccination serum HI antibody titer ≥1:40) were all greater than 80% (the lowest lower limit of the two-sided 95% CI was 85.09%). The GMTs increased more than 7-fold compared to pre-vaccination levels for all strains. The immunogenicity of all 4 influenza virus strains met the pre-specified criteria (lower limit of the two-sided 95% CI for SCR ≥ 30%, and lower limit of the two-sided 95% CI for SPR ≥ 60%11). Table 4.Pre-vaccination HI titers by group (<1:10 and <1:40).ClassificationPre-vaccnationHI titerLQIV-01N = 868H-QIVN = 860LQIV-02N = 870合计(N = 2598)PH1N1<1:10857 (98.7%)856 (99.5%)865 (99.4%)2578 (99.2%).1363<1:40868 (100%)860 (100%)869 (99.9%)2597 (0.0%)1.0000H3N2<1:10605 (69.7%)600 (69.8%)632 (72.6%)1837 (70.7%).3064<1:40654 (75.3%)656 (76.3%)682 (78.4%)1992 (76.7%).3048B/Yamagata<1:10188 (21.7%)211 (24.5%)201 (23.1%)600 (23.1%).3661<1:40742 (85.5%)725 (84.3%)740 (85.1%)2207 (84.9%).7877B/Victoria<1:10687 (79.1%)710 (82.6%)717 (82.4%)2114 (81.4%).1230<1:40713 (82.1%)733 (85.2%)750 (86.2%)2196 (84.5%).0528 Pre-vaccination HI titers by group (<1:10 and <1:40). Table 5.Immunogenicity data of participants. LQIV-01N = 868H-QIVN = 860LQIV-02N = 870LQIV-01 /LQIV-02Comparison*(95% CI)H-QIV/LQIV-02Comparison*(95% CI)H-QIV/LQIV-01Comparison*(95% CI)Prevaccination GMT (95% CI) H1N15.04 (5.02, 5.07)5.02 (5.00, 5.04)5.04 (5.00, 5.08)–––H3N210.71 (9.85, 11.65)10.59 (9.74, 11.52)9.69 (8.96, 10.47)–––B/Yamagata13.46 (12.81, 14.14)13.01 (12.37, 13.67)13.25 (12.60, 13.93)–––B/Victoria8.91 (8.22, 9.66)8.03 (7.46, 8.64)7.95 (7.39, 8.56)–––Postvaccination SCR (95% CI) H1N194.93% (93.25%, 96.29%)98.02% (96.85%, 98.84%)90.69% (88.56%, 92.54%)4.24% (1.82%, 6.66%)7.33% (5.19%, 9.48%)3.09% (1.36%, 4.82%)H3N285.60% (83.09%, 87.87%)93.14% (91.24%, 94.74%)90.34% (88.19%, 92.23%)−4.75% (−7.80%, −1.69%)2.79% (0.21%, 5.38%)7.54% (4.66%, 10.42%)B/Yamagata82.37% (79.67%, 84.85%)89.88% (87.67%, 91.82%)74.48% (71.45%, 77.35%)7.89% (4.04%, 11.74%)15.40% (11.87%, 18.93%)7.51% (4.27%, 10.75%)B/Victoria96.31% (94.84%, 97.46%)98.84% (97.87%, 99.44%)90.34% (88.19%, 92.23%)5.97% (3.64%, 8.30%)8.49% (6.40%, 10.58%)2.52% (1.08%, 3.97%)GMT (95% CI) H1N1140.92 (132.76, 149.58)206.91 (195.88, 218.56)123.99 (116.14, 132.38)1.1363 (1.0401, 1.2414)1.6682 (1.5317, 1.8169)1.4715 (1.3570, 1.5955)H3N2139.69 (128.85, 151.44)185.13 (171.87, 199.41)144.72 (134.02, 156.27)0.9083 (0.8323, 0.9912)1.2147 (1.1172, 1.3206)1.3341 (1.2241, 1.4539)B/Yamagata117.56 (108.51, 127.36)147.14 (136.58, 158.51)93.97 (86.70, 101.85)1.2379 (1.1162, 1.3729)1.5836 (1.4318, 1.7515)1.2790 (1.1573, 1.4134)B/Victoria184.00 (169.35, 199.92)238.06 (221.22, 256.18)119.72 (109.78, 130.56)1.3992 (1.2916, 1.5158)1.9725 (1.8232, 2.1340)1.3990 (1.2981, 1.5077)GMI (95% CI) H1N127.94 (26.32, 29.65)41.22 (39.01, 43.54)24.60(23.03, 26.28)–––H3N213.04 (12.14, 14.01)17.48 (16.32, 18.73)14.94(13.97, 15.98)–––B/Yamagata8.73 (8.11, 9.41)11.31 (10.53, 12.16)7.09(6.58, 7.65)–––B/Victoria20.64 (19.50, 21.85)29.64 (28.03, 31.34)15.06(14.19, 15.99)–––SPR (95% CI) H1N194.93% (93.25%, 96.29%)98.02% (96.85%, 98.84%)90.69% (88.56%, 92.54%)–––H3N290.78% (88.66%, 92.62%)95.70% (94.12%, 96.95%)93.10% (91.21%, 94.70%)–––B/Yamagata92.05% (90.05%, 93.76%)96.63% (95.19%, 97.73%)87.47% (85.09%, 89.60%)–––B/Victoria96.77% (95.37%, 97.85%)98.95% (98.02%, 99.52%)90.69% (88.56%, 92.54%)–––CI: confidence interval; GMT: geometric mean titer; GMI: geometric mean increase; SCR: seroconversion rate; SPR: seroprotection rate. *GMT comparison is based on the GMT ratio; SCR comparison is based on the SCR difference. Immunogenicity data of participants. CI: confidence interval; GMT: geometric mean titer; GMI: geometric mean increase; SCR: seroconversion rate; SPR: seroprotection rate. *GMT comparison is based on the GMT ratio; SCR comparison is based on the SCR difference. First, H-QIV and LQIV-01 were compared to LQIV-02 to demonstrate their non-inferiority in immunogenicity, measured by intergroup GMT ratios and SCR differences. The SCR differences and their 95% CIs for H1N1, H3N2, B/Yamagata and B/Victoria strains were 4.24% (1.82%, 6.66%), −4.75% (−7.80%, −1.69%), 7.89% (4.04%, 11.74%) and 5.97% (3.64%, 8.30%) between LQIV-01 and LQIV-02 groups. The SCR differences and their 95% CIs for H1N1, H3N2, B/Yamagata and B/Victoria strains were 7.33% (5.19%, 9.48%), 2.79% (0.21%, 5.38%), 15.40% (11.87%, 18.93%) and 8.49% (6.40%, 10.58%) between H-QIV and LQIV-02 groups. The lower limits of the two-sided 95% CIs for SCR differences were greater than −10% for all strains. The GMT ratios and their 95% CIs were 1.1363 (1.0401, 1.2414), 0.9083 (0.8323, 0.9912), 1.2379 (1.1162, 1.3729) and 1.3992 (1.2916, 1.5158) between LQIV-01 and LQIV-02 groups. The GMT ratios and their 95% CIs were 1.6682 (1.5317, 1.8169), 1.2147 (1.1172, 1.3206), 1.5836 (1.4318, 1.7515) and 1.9725 (1.8232, 2.1340) between H-QIV and LQIV-02 groups. The lower limits of the two-sided 95% CIs for GMT ratios were greater than 0.67 for all strains. The results show that LQIV-01 and H-QIV were non-inferior to LQIV-02. Subsequently, H-QIV was compared to L-QIVs. The lower limits of the two-sided 95% CIs for post-vaccination SCR differences were ≥0 between the H-QIV group and the LQIV-01 group/LQIV-02 group. The lower limits of the two-sided 95% CIs for post-vaccination GMT ratios were ≥1 between the H-QIV group and the LQIV-01 group/LQIV-02 group. The results show that H-QIV was superior to LQIV-01 and LQIV-02 in SCR and GMT against all 4 strains. Discussion Influenza is a major cause of morbidity and mortality in children worldwide, and seasonal influenza vaccination programs are implemented annually to reduce the disease burden.12–17 In China, however, influenza vaccines for children aged 6–35 months are predominantly low-dose (0.25 mL/dose), containing 7.5 μg hemagglutinin per strain, half the amount (15 μg hemagglutinin per strain) used for individuals aged ≥3 y. This dose reduction to 0.25 mL originated in the 1970s when whole-virion vaccines were associated with a high incidence of pyrexia and febrile convulsions in children aged <3 y.18,19 Nowadays, whole-virion vaccines have been replaced by split-virion and subunit vaccines, which possess lower reactogenicity.20,21 In many countries, 0.5 mL inactivated influenza vaccines (TIV, QIV) have been approved and used in children aged 6–35 months. This study aimed to evaluate and compare the safety and immunogenicity of high-dose and low-dose QIVs in children aged 6–35 months, providing a rationale for optimizing influenza vaccination strategies for this age group in China. The study results show that within 30 d post-vaccination, H-QIV exhibited >11-fold increase in GMTs against H1N1, H3N2, B/Yamagata and B/Victoria strains compared to pre-vaccination levels, with SPRs exceeding 95% and SCRs exceeding 89%; H-QIV was superior to LQIV-01 and LQIV-02 in all immunogenicity endpoints. These findings are consistent with multiple studies indicating that high-dose vaccines can induce a stronger immune response.8,9,22–24 The two dose levels in the study showed a comparable safety profile. There was no significant difference in the incidence of AEs between high and low dose levels in children. The observed safety profile, where higher antigen concentration was not associated with higher incidence of adverse reactions, aligns with previous reports.25–30 The incidences of SAEs were 9.6%, 9.9% and 10.6% in H-QIV, LQIV-01 and LQIV-02 groups, and only 3 of them were assessed as serious adverse reactions (SARs), 2 in the LQIV-02 group, further supporting the safety of the vaccine. In this study, the local AEs post-vaccination across groups mainly included vaccination site erythema and vaccination site swelling, and the systemic AEs post-vaccination mainly included pyrexia, diarrhea, vomiting, rhinorrhea, decreased appetite and irritability, which were basically consistent with previously reported adverse reactions for influenza vaccine.9,31,32 This study has two limitations: We did not investigate the immune persistence post-vaccination, and we did not evaluate vaccine efficacy. Although previous studies have established a correlation between antibody titers and protection against influenza, further validation through real-world studies is still necessary. In addition, despite the WHO’s recommendation to exclude B/Yamagata lineage antigen from influenza vaccine composition,33 TIVs and QIVs are still commercially available in China. While the 0.5 mL QIV (H-QIV) evaluated in this study exhibited excellent immunogenicity and safety, future influenza vaccination strategies in China may require further evaluation regarding the use of TIVs and QIVs in light of the updated WHO recommendations. Conclusion In summary, the findings of this study indicate that children receiving H-QIV have higher antibody titers against H1N1, H3N2, B/Yamagata and B/Victoria strains compared to those receiving L-QIV. These findings support the administration of two 0.5 mL doses of an influenza vaccine annually to children aged 6–35 months—a high-risk population—to confer superior protection. Acknowledgments We extend our sincere gratitude to the participants and their parents for their support of this project. We also acknowledge the staff from Qiubei County Center for Disease Control and Prevention, Yanshan County Center for Disease Control and Prevention, Qin County Center for Disease Control and Prevention and Luzhou District Center for Disease Control and Prevention for their contributions to this study. Biographies Yehong Wu, Director of Reaserch and Development Department & Head of Biosafety Level III Laboratory & Deputy General Manager, Changchun Institute of Biological Products Co., Ltd. Ph.D. Committed to the development of viral vaccines. Published numerous articles in virology and vaccine-related journals, such as the Chinese Journal of Biologicals. Won the Changchun City Award for Achievement Transformation of Quadrivalent Influenza Split-Virion Vaccine. Xiaoqiang Liu, Director of the Vaccine Clinical Research Center at Yunnan Provincial Center for Disease Control and Prevention. With over 15 years of experience in vaccinology, Dr. Liu has led numerous vaccine clinical trials and immunization program evaluations in China. His research focuses on vaccine safety, immunogenicity, and effectiveness assessment, particularly for influenza, pneumococcal, and COVID-19 vaccines. He has authored more than 30 peer-reviewed publications in international journals, including Human Vaccines & Immunotherapeutics, The Lancet Infectious Diseases, and Vaccine. Guohua Li, Director of the Vaccine Joint Development Center at Shanxi Provincial Center for Disease Control and Prevention. She has over 35 years of experience in disease prevention and control. She has successfully led numerous trials, including HPV vaccines, 13-valent pneumococcal conjugate vaccine and ACYW135 meningococcal polysaccharide vaccine. Funding Statement This project was funded by the Jilin Provincial Science and Technology Development Program, China under Grant numbers [20250301052YY]. Disclosure statement No potential conflict of interest was reported by the author(s). References